Summary
Vertex Pharmaceuticals announced a significant milestone with the U.S. Food and Drug Administration's approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) on December 19, 2024. This new therapy targets cystic fibrosis (CF) in patients aged 6 and older who possess at least one F508del mutation or another responsive mutation in the CFTR gene. The approval represents a key advancement in Vertex's CF franchise and offers a new treatment option for a broad segment of the CF patient population. The company has also set the wholesale acquisition cost (WAC) for ALYFTREK in the United States at $370,269 annually, or $28,404 per 28-day pack. This pricing, while substantial, is typical for advanced therapies in the rare disease space and will be a crucial factor for payers and patients to consider. Investors will be closely watching market uptake and reimbursement dynamics for ALYFTREK as it launches.
Key Highlights
- 1FDA approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for cystic fibrosis.
- 2ALYFTREK targets patients aged 6+ with specific CFTR gene mutations (including F508del).
- 3Approval date: December 19, 2024.
- 4Annual U.S. Wholesale Acquisition Cost (WAC) set at $370,269.
- 5Per 28-day pack cost established at $28,404.
- 6This filing is made under Regulation FD.
- 7The information is not deemed 'filed' for Section 18 liability purposes.